CDP-870 (certolizumab) in rheumatoid arthritis.
University of Liverpool Academic Rheumatology Unit, Clinical Sciences Centre, University Hospital Aintree, Longmoor Lane, Liverpool, L97AL, UK.
The development of biological anti-TNF-alpha therapy has revolutionised the treatment of rheumatoid arthritis and other inflammatory diseases, and has identified a worldwide market for expensive yet effective therapies for chronic diseases. Certolizumab (CDP-870) is a new agent that employs a novel strategy to neutralise TNF-alpha--namely the prokaryotic expression of TNF-alpha-specific Fab antibody fragments, coupled to polyethylene glycol--to produce a drug that is potentially less expensive to manufacture than other anti-TNF-alpha agents and which may be administered by subcutaneous injection once a month. The background to the ongoing development of this new agent and its clinical effects are discussed in this article.
PMID: 15934837 [PubMed - indexed for MEDLINE]